Tactile Systems Technology (NASDAQ:TCMD) Posts Earnings Results, Beats Estimates By $0.09 EPS

Tactile Systems Technology (NASDAQ:TCMD) announced its quarterly earnings data on Tuesday. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.09, Zacks reports. Tactile Systems Technology had a return on equity of 9.24% and a net margin of 5.42%. Tactile Systems Technology updated its FY 2025 guidance to EPS.

Tactile Systems Technology Stock Up 3.1 %

TCMD stock traded up $0.53 during trading on Tuesday, reaching $17.86. 413,672 shares of the stock were exchanged, compared to its average volume of 247,992. The company has a current ratio of 4.37, a quick ratio of 3.80 and a debt-to-equity ratio of 0.12. The firm’s 50 day moving average is $17.45 and its 200 day moving average is $15.61. The firm has a market cap of $428.64 million, a P/E ratio of 27.48 and a beta of 1.20. Tactile Systems Technology has a twelve month low of $11.12 and a twelve month high of $21.10.

Analysts Set New Price Targets

TCMD has been the topic of a number of research reports. Oppenheimer downgraded Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. BTIG Research downgraded Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 5th. Finally, StockNews.com downgraded Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 16th.

About Tactile Systems Technology

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.